Wheeler, DC;
(2021)
Chlorthalidone in Advanced Chronic Kidney Disease - Have We Missed a Trick?
New England Journal of Medicine
, 385
(27)
pp. 2574-2575.
10.1056/NEJMe2118149.
Preview |
Text
nejme2118149.pdf - Published Version Download (356kB) | Preview |
Abstract
Control of hypertension is central to the management of chronic kidney disease, both to preserve residual kidney function and to reduce the associated high risk of cardiovascular events. International guidelines recently updated by the Kidney Disease: Improving Global Outcomes Organization recommend that patients with chronic kidney disease and hypertension be treated to reduce standardized office systolic blood pressure to less than 120 mm Hg, unless there are obvious reasons not to do so. This ambitious target is difficult to achieve with currently available antihypertensive medications, particularly in patients with more advanced chronic kidney disease (stages 4 and 5)
| Type: | Article |
|---|---|
| Title: | Chlorthalidone in Advanced Chronic Kidney Disease - Have We Missed a Trick? |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1056/NEJMe2118149 |
| Publisher version: | https://doi.org/10.1056/NEJMe2118149 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Renal Medicine |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10141835 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
